| 1.7 -0.03 (-1.73%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.12 | 1-year : | 2.44 |
| Resists | First : | 1.81 | Second : | 2.08 |
| Pivot price | 1.8 |
|||
| Supports | First : | 1.37 | Second : | 1.14 |
| MAs | MA(5) : | 1.8 |
MA(20) : | 1.73 |
| MA(100) : | 2.08 |
MA(250) : | 1.5 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 52.1 |
D(3) : | 64.5 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 3.81 | Low : | 0.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IBIO ] has closed above bottom band by 25.6%. Bollinger Bands are 35.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.81 - 1.82 | 1.82 - 1.83 |
| Low: | 1.64 - 1.65 | 1.65 - 1.66 |
| Close: | 1.68 - 1.7 | 1.7 - 1.72 |
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
Mon, 08 Jun 2026
Raymond James initiates iBio stock coverage with outperform rating By Investing.com - Investing.com South Africa
Fri, 05 Jun 2026
B. Riley Initiates IBio at Buy With $6 Price Target - Moomoo
Thu, 04 Jun 2026
IBIO: Advancing antibody-based therapies for obesity, muscle preservation, and weight maintenance - TradingView
Tue, 02 Jun 2026
AI drug developer iBio joins two health investor events in June and July 2026 - Stock Titan
Tue, 02 Jun 2026
iBio to Participate in Upcoming Healthcare Investor Conferences - Yahoo Finance
Tue, 02 Jun 2026
iBio tests long-acting obesity antibody designed to preserve muscle - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 3.932e+007 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 3,640 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.827e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 653 % |
| Return on Equity (ttm) | -34.5 % |
| Qtrly Rev. Growth | 300000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -51.64 |
| EBITDA (p.s.) | 220588 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 3.41e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|